1Johnson DH, Fehrenbacher L, Novotny WF. et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol, 2004, 22(11): 2184-2191.
2Sandier A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med, 2006, 355(24): 2542-2550.
3Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAIL. J Clin Oncol, 2009, 27(8): 1227-1234.
4Reck M, von PawelJ, Zatloukal P, et al. Overall survival with cisplatin/ gemcitabine and bevacizumab or placebo as first-line therapy for non squamous non-small cell lung cancer: results from a randomised phase III trial (AVAIL). Ann Oncol, 2010, 21(9): 1804-1809.
5Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAIL, MO19390): a phase 4 study. Lancet Oncol, 2010, 11(8): 733-740.
6Fukuoka M, Wu YL, Thongprasert S, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first- line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol, 2011, 29(21): 2866-2874.
7Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N EnglJ Med, 2009, 361(10): 947-957.
8Tsai CM, AuJS, Chang GC, et al. Safety and efficacy of first-line bevacizumab with chemotherapy in Asian patients with advanced nonsquamous NSCLC: results from the phase IV MO19390 (SAIL) study. J Thorac Oncol, 2011, 6(6): 1092-1097.
9Sinpkins F,Belinson JL,Rose PG. Avoiding bevacizum abrelated gastro in testinal toxicity f or recrrent ovarian cancer by careful patient screening[J].Gynecologic Oncology,2007,(01):118-123.
10Burger RA,SillMW,Monk BJ. Phase & trial of bevacizum ab in persistent or recu rren t epithelial ovari an cancer or primary peritoneal cancer:a Gynecologic Oncology Group St udy[J].J Clin Oncol,2007,(33):5165-5171.
